%0 Journal Article
%T Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation
%A Lubica Roziakova
%A Eva Bojtarova
%A Martin Mistrik
%A Juraj Dubrava
%A Jozef Gergel
%A Nadezda Lenkova
%A Beata Mladosievicova
%J Journal of Experimental & Clinical Cancer Research
%D 2012
%I BioMed Central
%R 10.1186/1756-9966-31-13
%X Thirty-seven patients who were treated with allogeneic HSCT for hematologic diseases at median age of 28 years at time of HSCT were studied. Conditioning regimen included either chemotherapy without total body irradiation (TBI) or combination of chemotherapy with TBI. Twenty-nine (78,3%) patients were pretreated with ANT therapy. Cardiac biomarkers were serially measured before conditioning regimen and at days 1, 14 and 30 after HSCT. Cardiac systolic and diastolic functions were assessed before conditioning regimen and 1 month after HSCT by echocardiography.The changes in plasma NT-proBNP and hs-cTnT levels during the 30 days following the HSCT were statistically significant (P < 0,01 v.s. P < 0,01). Persistent elevations of NT-proBNP and hs-cTnT simultaneously for a period exceeding 14 days after HSCT were found in 29,7% patients. Serum concentrations of cardiomarkers were significantly elevated in ANT group compared to non-ANT group. These observations were underscored by the echocardiographic studies which did reveal significant changes in systolic and diastolic parameters. Five of 37 (13,5%) patients developed clinical manifestation of cardiotoxicity.Elevations in both cardiac biomarkers were found before clinical signs of cardiotoxicity developed. Persistent elevations in NT-pro-BNP and hs-cTnT concentrations simultaneously for a period exceeding 14 days might be used for identification of patients at risk of developing cardiotoxicity and requiring further cardiological follow up.Stem cells are widely used in the treatment of malignant and nonmalignant diseases [1]. Advances in allogeneic hematopoietic stem cell transplantation (HSCT) have increased survival in hematologic diseases. Among those who survive the first 2 years, nearly 80% of allogeneic HSCT recipients are expected to become long-term survivors and by 2020 there may be up to half a million of these survivors worldwide [2,3].However, HSCT survivors are at risk of developing long-term complications.
%K Hematopoietic stem cell transplantation
%K Cardiotoxicity
%K Natriuretic peptides
%K Cardiac troponins
%U http://www.jeccr.com/content/31/1/13